Aortic Aneurysm, Thoracic

In its first 12 months, the surveillance program has led to 35 life-saving TAA surgical procedures. OVERLAND PARK, Kan., Feb. 20, 2024 /PRNewswire/ -- Softek Illuminate, Inc., provider of enterprise follow-up management and discovery software, and UC Davis Health have developed a centralized Thoracic Aortic Aneurysm (TAA) surveillance program that is saving lives. The effort has identified at-risk patients who may have been 'lost-to-follow-up' because they missed care due to numerous factors. This new program builds on the previously announced success between Illuminate and UC Davis Health with a centralized Abdominal Aortic Aneurysm (AAA) program. This new TAA program will further advance efforts to make it easier for care navigators to manage vascular patients with critical follow-up care requirements. In the first 12 months of the program, which kicked-off December 2022, over 21,700 patients have been identified with some mention of TAA who could benefit from ongoing surveillance. Over 12,200 TAA patient records were then reviewed and 2,390 patients who were lost to care are now under active surveillance and management by nurse navigators. Of those, 146 patients visited UC Davis Health, which resulted in 461 diagnostic imaging studies and 35 life-saving TAA surgical procedures. "Through the TAA surveillance program, we have been able to improve patient outcomes by reducing the risk of a patient experiencing an aneurysm rupture by offering TAA repair when appropriate," said Misty Humphries, interim chief of Vascular Surgery at UC Davis Health. "This is but one example of how we are using cutting edge software technology to improve patient care and clinical outcomes." According to the Society for Vascular Surgery, each year 15,000 people in the United States are diagnosed with a TAA. As a leading academic medical center with a patient-centered focus on digital health, UC Davis Health has implemented the Discovery 360 Platform and ActKnowledge AI software by Illuminate. The goal is to identify existing patients in the UC Davis electronic health record who may have a TAA and who need follow-up care. Identified patients are then contacted by a UC Davis Health nurse navigator who explains the program and the process. The nurse also educates the patient about the importance of follow-up and ongoing surveillance by their primary care physician and serves as an educational resource for the patient when they have additional questions. Along with Illuminate AI technology and clinical process understanding, the Illuminate Discovery 360™ Platform incorporates skilled Illuminate nurse navigators with expertise in patient follow-up and management workflow. Their participation can lower the barrier for implementing a comprehensive aneurysm surveillance program and ensure the following benefits are realized: Improve Follow-Up Compliance. Eliminate Gaps in Care. Align follow-up care with health system care guidelines. Retain Patients In-Network and Reducing Leakage. Avert Ruptures and Saves Lives. "We are excited about our expanded relationship with UC Davis Health and these very positive results that align with our previous success in the AAA space," states Cole Erdmann, CEO, Softek Illuminate, Inc.. About Softek Illuminate, Inc. Illuminate is the industry-leading provider of end-to-end discovery, follow-up, and patient management solutions. We achieve this by combining our advanced AI-powered patient management platform with our nurse navigator's knowledge of integrated clinical workflows and follow-up processes. The Illuminate Platform enables healthcare organizations to provide the highest quality and most cost-effective care while growing revenue throughout the patient journey. Illuminate simplifies the process of ensuring that the right care team manages the appropriate patients at the right time. To learn more, visit . SOURCE Softek Illuminate, Inc.

PHILADELPHIA, Nov. 15, 2023 /PRNewswire/ -- Jefferson is pleased to announce that Joseph E. Bavaria, MD is joining Jefferson Health and Sidney Kimmel Medical College, effective January 15, 2024. Dr. Bavaria brings a wealth of leadership and surgical expertise to Jefferson's expanding team as it continues to advance the diagnosis, treatment and prevention of heart and vascular conditions. Continue Reading Dr. Bavaria will join Jefferson from Penn Medicine where he serves as Vice Chief, Division of Cardiovascular Surgery, Director of the Thoracic Aortic Surgery Program, Co-Director of the Transcatheter Valve Program and Founder and Co-Director of the Penn Aorta Center. Dr. Bavaria brings a wealth of leadership and surgical expertise to Jefferson's expanding team. Post this "Dr. Bavaria's distinguished career in cardiovascular research and surgical advancements make him a valuable addition to Jefferson's expanding Heart and Vascular program," said Baligh Yehia, MD, MPP, MSc, FACP, President of Jefferson Health. "Jefferson has a rich legacy of delivering innovative cardiovascular healthcare services throughout the region, and Dr. Bavaria's expertise will only strengthen our commitment to providing leading-edge, compassionate care to all we serve." Having performed more than 9,000 open heart procedures in his career, Dr. Bavaria is an expert in treating thoracic aortic aneurysms and repairing and replacing aortic valves. He is a skilled lecturer and educator, has held national and international leadership positions including president of the Society of Thoracic Surgeons (STS), president of the Thoracic Surgery Foundation, board member of the Heart Valve Society, and executive committee member of the European Association of CardioThoracic Surgery (EACTS). Dr. Bavaria has also played a pivotal role in helping to establish national treatment guidelines. "We are honored to welcome Dr. Bavaria to the Sidney Kimmel Medical College. With a legacy of groundbreaking contributions to cardiovascular medicine, Dr. Bavaria brings unparalleled expertise that will undoubtedly inspire and shape the future generation of surgeons here at Thomas Jefferson University," said Susan C. Aldridge, PhD, Interim President, Thomas Jefferson University. "This is a unique time to be joining Jefferson as the organization focuses on integrating cardiovascular services throughout the system. I look forward to being a part of Jefferson's efforts to bring world-class care to those most in need," said Joseph E. Bavaria, MD. Dr. Bavaria earned a Bachelor of Science degree and Medical degree from Tulane University in New Orleans. He completed his surgical internship and residency at the Hospital of the University of Pennsylvania and completed additional residencies in thoracic and cardiovascular surgery at the Hospital of the University of Pennsylvania and Children's Hospital of Philadelphia. About Jefferson Nationally ranked, Jefferson, which is principally located in the greater Philadelphia region and southern New Jersey, is reimagining healthcare and higher education to create unparalleled value. Jefferson is more than 42,000 people strong, dedicated to providing the highest-quality, compassionate clinical care for patients; making our communities healthier and stronger; preparing tomorrow's professional leaders for 21st-century careers; and creating new knowledge through basic/programmatic, clinical, and applied research. Thomas Jefferson University, home of Sidney Kimmel Medical College and Kanbar College of Design, Engineering, and Commerce, is a national doctoral research university that dates back to 1824 and today comprises 10 colleges and three schools offering 200 undergraduate and graduate programs to more than 8,400 students. Jefferson Health, nationally ranked as one of the top healthcare systems in the country and the largest provider in the Philadelphia area, serves patients through millions of encounters each year at 17 hospitals and over 50 outpatient and urgent care locations throughout the region. Jefferson Health Plans is a not-for-profit managed health care organization providing a broad range of health coverage options in Pennsylvania and New Jersey for more than 35 years. SOURCE Jefferson

CAMBRIDGE, Mass., Nov. 1, 2023 /PRNewswire/ -- ConcertAI's TeraRecon, a leader in advanced visualization and AI Clinical SaaS, is pleased to announce an expanded collaboration with Avicenna.AI, a specialist in medical imaging AI. Together, they will provide global solutions that leverage artificial intelligence to enhance care coordination and improve patient triage for individuals afflicted with pulmonary embolism (PE) and aortic dissection (AD). This collaboration aims to expedite clinical decision-making and optimize patient care for these critical medical conditions. Diagnosing and coordinating care for patients facing PE and AD pose significant hurdles. Avicenna.AI has FDA approval for its algorithms, tailored for PE and both Type A and Type B AD, which will seamlessly integrate into the Eureka Clinical AI platform. This integration aims to streamline identification of these conditions, thus empowering multidisciplinary patient care coordination. Upon detecting a PE or AD, the Eureka Clinical AI platform will rapidly notify each provider's desktop or mobile device, delivering dynamic imaging and comprehensive patient information. Additionally, the aortic module offering will grant access to imaging and workflows supporting coordinated care for patients with abdominal aortic aneurysm (AAA), thoracic aortic aneurysm (TAA), rupture, stenosis, and transection, alongside the AD algorithm. Likewise, the PE algorithm will be accessible through the Eureka Clinical AI platform's PE module. The inclusion of AI-powered workflows via the Eureka Clinical AI platform is anticipated to significantly reduce the time it takes a physician to diagnose these potentially life threating conditions to treatment by facilitating more informed treatment decisions across health systems. Through the incorporation of Avicenna's PE and AD solutions, coupled with the existing CINA-iPE on the Eureka Clinical AI platform for the EU, TeraRecon is positioned to offer enhanced pulmonary and aortic solutions to its global clientele of approximately 1,900 customers. "We are dedicated to expanding the Eureka Clinical AI ecosystem with impactful AI solutions that support our clinicians and care providers," said Dan McSweeney, President of TeraRecon. "Avicenna's solutions play a crucial role in fulfilling this commitment by broadening access to essential triage capabilities through our scalable Eureka Clinical AI platform." Avicenna.AI specializes in providing healthcare AI solutions that utilize deep learning to identify, detect, and quantify life-threatening pathologies from CT images. By employing a blend of deep learning and machine learning technologies, the company's solutions autonomously detect and prioritize emergency cases within seconds, assess their severity, and promptly notify radiologists. "We are excited to empower TeraRecon users worldwide with our groundbreaking AI-driven solutions for the care coordination of pulmonary embolism and aortic dissection," said Cyril Di Grandi, Chief Executive Officer of Avicenna.AI. "Our aim is to expedite an optimal medical response within a short timeframe and enhance patient care. We eagerly anticipate extending the benefits of our pulmonary embolism and aortic dissection triage tools to the emergency room and beyond." Eureka Clinical AI stands as the foremost AI SaaS imaging interpretation and clinical decision augmentation solution from ConcertAI's TeraRecon. Distinguished as the industry's most widely deployed platform, it uniquely accommodates third-party AI algorithms, facilitating consolidated management of all AI interpretation solutions with seamless PACS integrations. Multi-specialty care teams can swiftly access results and receive mobile alerts to confirm AI findings, ensuring optimal and timely patient interventions, management, and coordinated care delivery. To learn more about the Eureka Clinical AI platform, its capabilities, and algorithms spanning neurology, radiology, cardiology, oncology, and more, visit: . About TeraRecon: Serving approximately 1,900 clinical sites globally, TeraRecon, a ConcertAI company, is a Best in KLAS solution provider for AI-empowered radiology, oncology, cardiology, neurology, and vascular surgery. Awarded the KLAS Category Leader for Advanced Visualization, TeraRecon solutions are independent of any one manufacturer's imaging equipment or PACS, allowing a single, unified, and simplified clinical workflow that can improve efficiencies and deliver actionable physician-guided insights. For more information, visit us at About ConcertAI: ConcertAI is the leader in Real-World Evidence (RWE) and AI technology solutions for life sciences and health care. Our mission is to accelerate insights and outcomes for patients through leading real-world data, AI technologies, and scientific expertise in partnership with the leading biomedical innovators, health care providers, and medical societies. For more information, visit us at or follow us on LinkedIn. About Avicenna.AI: Founded in 2018, Avicenna.AI develops medical imaging AI solutions for highly prevalent pathologies. The company uses artificial intelligence and deep learning to optimize many of a radiologist's manual tasks. Its CINA products leverage deep learning algorithms to identify acute abnormalities and to enhance clinicians' workflow. Avicenna.AI is co-founded by Cyril Di Grandi, who previously co-founded and successfully sold Olea Medical, and Dr. Peter Chang, a radiologist and internationally recognized expert in AI and deep learning. Media Contact: Megan Duero, [email protected] SOURCE ConcertAI